TABLE 1.
Subjects included in the analysis, from enrollment to final number with complete data, n (%)1
| Southern Asia | Latin America | Sub-Saharan Africa | Total | |||||
|---|---|---|---|---|---|---|---|---|
| BGD | INV | NEB | BRF | PEL | SAV | TZH | ||
| Enrolled | 265 | 251 | 240 | 233 | 303 | 314 | 262 | 1868 |
| Follow-up to 2 y2 | 213 (80) | 228 (91) | 228 (95) | 169 (73) | 208 (69) | 237 (75) | 215 (82) | 1498 (80) |
| Anthropometry at 5 y3 | 193 (91) | 213 (93) | 128 (56) | 131 (78) | 164 (79) | 183 (77) | 176 (82) | 1188 (79) |
| Complete illness, pathogen history, and complementary diet data during early childhood4 | 193 (100) | 212 (99) | 127 (99) | 111 (85) | 154 (94) | 164 (90) | 170 (97) | 1131 (95) |
| Complete data on other variables5 | 186 (96) | 207 (97) | 122 (95) | 99 (76) | 145 (88) | 132 (72) | 126 (71) | 1017 (86) |
Sites: BGD: Bangladesh—Dhaka; INV: India—Vellore; NEB: Nepal—Bhaktapur; BRF: Brazil—Fortaleza; PEL: Peru—Loreto; SAV: South Africa—Venda; TZH: Tanzania—Haydom.
Children with follow-up to 2 y included in analyses of 2-y growth outcomes (percentage of those enrolled).
Children with height and weight at 5 y of age (percentage of those still in study at 2 y). In SAV (4) and NEB (99), children were older than 62 mo when funding (SAV) or ethical clearance (NEB) was obtained.
Children with at least 700 d of illness surveillance, 11 measures of dietary intake from 9 to 24 mo, 8 stool samples to detect enteropathogens and fecal biomarkers of gut inflammation (percentage of those in the follow-up study).
Children with data on maternal height, micronutrient status and L:M test results (percentage of those in the follow-up study).